Cautious Hold on Biogen Amid Modest Growth Prospects and Uncertain Pipeline

Tim Anderson, an analyst from Bank of America Securities, reiterated the Hold rating on Biogen. The associated price target was lowered to $142.00.

Tim Anderson’s rating is based on Biogen’s current valuation and growth outlook. Despite being one of the more affordable options in the large-cap biopharma sector, Biogen’s growth prospects appear modest, with revenues and earnings per share expected to remain relatively flat in the coming years.
While the company’s Alzheimer’s drug, Leqembi, shows promise and continues to perform well, the overall pipeline of potential new drugs does not offer immediate breakthroughs. The potential for an upside exists if certain clinical trials yield positive results, but these are not expected in the near term. As such, the Hold rating reflects a cautious approach, acknowledging the company’s strengths while remaining aware of its limitations.

Anderson covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Amgen. According to TipRanks, Anderson has an average return of 9.0% and a 64.71% success rate on recommended stocks.